With sixty days until the start of 2023 it is a great time for researchers, whether in academia or in corporate settings, to evaluate our ocular instruments. Additional instrument information is here > https://tinyurl.com/mryam873. We welcome the opportunity to demo our products to you. Please register here
Read more →Good things come in 3’s! Nanoscope receives award (again) as part of the top research team in NEI 3-D ROC challenge Arlington, TX, September 20, 2022—Researchers at the University of Colorado led by Valeria Canto-Soler and those from Nanoscope® led by Samarendra Mohanty, PhD were recognized as
Read more →Nanoscope Therapeutics Appoints Pharma Industry Veteran Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer DALLAS, April 18, 2022 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, today announced Aaron Osborne, MBBS, was appointed Chief Medical Officer and Chief Development Officer.
Read more →